Laboratoire HRA Pharma SAS-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Laboratoire HRA Pharma SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011798
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Laboratoire HRA Pharma (HRA Pharma) is a healthcare products provider that offers women’s health and endocrinology products. The company offers a wide range of women’s health products which include emergency contraception, uterine fibroids, regular contraception and genital herp products among others. Its endocrinology products comprise advanced adrenal cortical carcinoma and cushing’s syndrome medicines; and lysosafe service devices. The company operates through partnerships with pharmaceutical companies, public and private institutions, healthcare professionals and others. It operates in France, Germany, Ireland, Italy, Switzerland, Spain, Portugal, Belgium and the UK. HRA Pharma is headquartered in Paris, France.

Laboratoire HRA Pharma SAS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Laboratoire HRA Pharma SAS, Medical Devices Deals, 2011 to YTD 2017 9
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
HRA Pharma Acquires Compeed from Cilag 11
HRA Pharma Acquires Ovarian Cancer Immunotherapy from Pantarhei Bioscience 12
Venture Financing 13
Embera NeuroTherapeutics Raises USD1.9 Million in Series A-2 Financing 13
Private Equity 14
Astorg Asset Management and Goldman Sachs Acquire Laboratoire HRA Pharma 14
Riverside Acquires Minority Stake in HRA Pharma 16
Partnerships 17
HRA Pharma Enters into Distribution Agreement with Laboratoires Carilene 17
Licensing Agreements 18
ASKA Pharma Enters into Licensing Agreement with HRA Pharma 18
Gedeon Richter Expands Licensing Agreement With HRA Pharma For Esmya 19
Gedeon Richter Expands Licensing Agreement With HRA Pharma 20
ASKA Pharma Enters Into Licensing Agreement With HRA Pharma For ellaOne 21
Asset Transactions 22
Gedeon Richter Acquires Esmya from Laboratoire HRA Pharma 22
Laboratoire HRA Pharma SAS – Key Competitors 23
Laboratoire HRA Pharma SAS – Key Employees 24
Laboratoire HRA Pharma SAS – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Corporate Communications 27
Jul 12, 2016: HRA Pharma Announces CEO Transition to Position Company for the Next Phase of Growth 27
Product News 28
11/21/2016: FIBRISTAL, The First And Only Medication Indicated For Uterine Fibroids, Receives Approval From Health Canada For Long Term Intermittent Treatment 28
01/20/2016: Depression experts question effectiveness of stress hormone drug 29
Clinical Trials 31
Jan 17, 2017: Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids 31
Oct 17, 2016: Allergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City 33
May 09, 2016: Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids 34
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Key Facts 2
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Laboratoire HRA Pharma SAS, Deals By Therapy Area, 2011 to YTD 2017 8
Laboratoire HRA Pharma SAS, Medical Devices Deals, 2011 to YTD 2017 9
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
HRA Pharma Acquires Compeed from Cilag 11
HRA Pharma Acquires Ovarian Cancer Immunotherapy from Pantarhei Bioscience 12
Embera NeuroTherapeutics Raises USD1.9 Million in Series A-2 Financing 13
Astorg Asset Management and Goldman Sachs Acquire Laboratoire HRA Pharma 14
Riverside Acquires Minority Stake in HRA Pharma 16
HRA Pharma Enters into Distribution Agreement with Laboratoires Carilene 17
ASKA Pharma Enters into Licensing Agreement with HRA Pharma 18
Gedeon Richter Expands Licensing Agreement With HRA Pharma For Esmya 19
Gedeon Richter Expands Licensing Agreement With HRA Pharma 20
ASKA Pharma Enters Into Licensing Agreement With HRA Pharma For ellaOne 21
Gedeon Richter Acquires Esmya from Laboratoire HRA Pharma 22
Laboratoire HRA Pharma SAS, Key Competitors 23
Laboratoire HRA Pharma SAS, Key Employees 24
Laboratoire HRA Pharma SAS, Other Locations 25
Laboratoire HRA Pharma SAS, Subsidiaries 25

★海外企業調査レポート[Laboratoire HRA Pharma SAS-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Amtrust Financial Services, Inc.:企業の戦略・SWOT・財務分析
    SummaryAmtrust Financial Services, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the com …
  • Athenex Inc (ATNX):製薬・医療:M&Aディール及び事業提携情報
    Summary Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC, is a biopharmaceutical company focused on the discovery, development and commercialization novel medicines and cell therapies for the treatment of cancers. The company’s orascovery products candidates include oral formulations of pac …
  • Plug Power, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Plug Power, Inc. Mergers and Ac …
  • Nidec Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Nidec Corporation Mergers and A …
  • Bachem Holding AG (BANB):製薬・医療:M&Aディール及び事業提携情報
    Summary Bachem Holding AG (Bachem) is a technology-based biochemical company which develops and manufactures peptides and complex organic molecules including active pharmaceutical ingredients and biochemicals for research purposes. Bachem offers its products and services to the pharmaceutical and bi …
  • Polyplank AB (POLY):企業概要、財務及び戦略的SWOT分析
    Summary Polyplank AB (Polyplank) is a recycling company. The company manufactures various products using proprietary recyclable composite materials consisting of recycled thermoplastics and organic fibers. Its products include recycling building, shielding fence and balconies, beachplank, system for …
  • Capsule Technologie S.A.:企業の戦略的SWOT分析
    Capsule Technologie S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Extendicare Inc (EXE):企業財務及び戦略的SWOT分析
    Summary Extendicare Inc (Extendicare), formerly Crownx Inc. is a healthcare service provider that provides long-term care services with a wide range of senior care centers. The centers provide services such as short stay care, convalescent care, home health care, group purchasing, assisted living, l …
  • Serodus ASA:製薬・医療:M&Aディール及び事業提携情報
    Summary Serodus ASA (Serodus) is a drug development company that develops treatments for unmet clinical needs in the areas of diabetes and diabetic comorbidities. The company’s pipeline products include SER150DN, an anti-inflammatory compound under development for diabetic nephropathy; SER130AMI, an …
  • Akzo Nobel NV (AKZA):企業の財務・戦略的SWOT分析
    Akzo Nobel NV (AKZA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • OJSC Orenburgneft:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' OJSC Orenburgneft Mergers and A …
  • Jupiter Energy Limited (JPR):企業概要、財務及び戦略的SWOT分析
    Summary Jupiter Energy Limited (Jupiter Energy) is an oil and gas company. The company explores, produces and develops oil and natural gas properties. Its oil production wells include J-50, J-51, J-52 and J-53 wells. Jupiter Energy uses 3D seismic processing and interpretation for drilling oil wells …
  • The Dhampur Sugar Mills Limited (DHAMPURSUG):企業概要、財務及び戦略的SWOT分析
    Summary The Dhampur Sugar Mills Limited (Dhampur Sugar Mills) is a sugarcane processing company. The company produces sugar, renewable power, fuel ethanol, alcochem, industrial gases, and bio-fertilizer. Its ethanol products include double refined white sulphur less sugar, plantation white sugar and …
  • Greenbelt Resources Corporation:企業のM&A・提携動向(発電分野)
    Summary Greenbelt Resources Corporation (GRC) is an alternative energy company that offers end- to- end waste- to- ethanol solutions. The company offers sustainable energy production systems that provide on delivering modular solutions that enable localized processing of locally generated waste into …
  • China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999):企業の財務・戦略的SWOT分析
    China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the …
  • Zyngenia Inc:企業のM&A・提携動向(医療分野)
    Summary Zyngenia Inc (Zyngenia) is a biopharmaceutical company that develops drugs for cancer, inflammation and autoimmune disorders. The company uses Zybody technology platform for creating monoclonal antibody based therapeutics. Its Zybody therapeutics are the single-protein combination therapeuti …
  • Arcion Therapeutics, Inc.(製薬・医療分野):企業M&A動向
    Summary Arcion Therapeutics, Inc. (Arcion) is a biotechnology company. The company develops a pipeline of product candidates to treat neuropathic pain, a complex and debilitating chronic pain state. Its pain programs include topical pain management and neuropathic pain. Arcion concentrates on topica …
  • Covanta Holding Corporation (CVA):電力:M&Aディール及び事業提携情報
    Summary Covanta Holding Corporation (Covanta) is a provider of sustainable waste and energy solutions. It generates electricity from its Energy-from-Waste (EfW); and recycles ferrous and non-ferrous metals through its subsidiaries. Its Energy-from-Waste (EfW) facilities convert more than 20 million …
  • Gulf Power Company:企業のM&A・提携動向(発電分野)
    Summary Gulf Power Company (Gulf Power) a subsidiary of Southern Company, is a vertically integrated energy utility which generates, procures, transmits, and distributes electricity. It generates electricity from coal and natural gas. The company has agreements with various industrial, commercial, a …
  • ADInstruments Pty Ltd:企業の戦略的SWOT分析
    ADInstruments Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆